[{"id":"0018e50a-caae-491b-91cf-6c6089e49567","acronym":"ICEBERG 1","url":"https://clinicaltrials.gov/study/NCT00494234","created_at":"2021-01-18T01:46:05.061Z","updated_at":"2024-07-02T16:35:22.866Z","phase":"Phase 2","brief_title":"Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer","source_id_and_acronym":"NCT00494234 - ICEBERG 1","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA1 positive","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 06/15/2007","start_date":" 06/15/2007","primary_txt":" Primary completion: 02/27/2009","primary_completion_date":" 02/27/2009","study_txt":" Completion: 12/21/2022","study_completion_date":" 12/21/2022","last_update_posted":"2024-01-19"},{"id":"ce3c6d4d-3557-41e3-b4e7-e3d008942381","acronym":"ICEBERG 3","url":"https://clinicaltrials.gov/study/NCT00628251","created_at":"2021-01-18T02:20:09.301Z","updated_at":"2024-07-02T16:36:52.848Z","phase":"Phase 2","brief_title":"Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer","source_id_and_acronym":"NCT00628251 - ICEBERG 3","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA1 positive","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • pegylated liposomal doxorubicin • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 07/30/2008","start_date":" 07/30/2008","primary_txt":" Primary completion: 09/15/2009","primary_completion_date":" 09/15/2009","study_txt":" Completion: 09/19/2018","study_completion_date":" 09/19/2018","last_update_posted":"2019-12-05"},{"id":"1eed90ed-5e9b-4135-a6d4-7238eeaa9424","acronym":"","url":"https://clinicaltrials.gov/study/NCT00494442","created_at":"2021-01-18T01:46:07.521Z","updated_at":"2024-07-02T16:37:08.386Z","phase":"Phase 2","brief_title":"Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer","source_id_and_acronym":"NCT00494442","lead_sponsor":"AstraZeneca","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA1 positive","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2007","start_date":" 06/11/2007","primary_txt":" Primary completion: 03/17/2009","primary_completion_date":" 03/17/2009","study_txt":" Completion: 07/20/2017","study_completion_date":" 07/20/2017","last_update_posted":"2018-08-01"},{"id":"d13dc623-7bf1-42f7-ae2f-c51d6db0c42a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00267072","created_at":"2021-01-18T00:54:31.455Z","updated_at":"2024-07-02T16:37:14.975Z","phase":"","brief_title":"Ovarian Screening Study","source_id_and_acronym":"NCT00267072","lead_sponsor":"University of Louisville","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA1 positive","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 positive"],"overall_status":"Completed","enrollment":" Enrollment 5000","initiation":"Initiation: 06/01/2001","start_date":" 06/01/2001","primary_txt":" Primary completion: 05/01/2010","primary_completion_date":" 05/01/2010","study_txt":" Completion: 05/01/2010","study_completion_date":" 05/01/2010","last_update_posted":"2018-01-09"},{"id":"c2b76a64-c851-4686-b3f8-eae4cd43775a","acronym":"REACH","url":"https://clinicaltrials.gov/study/NCT01346761","created_at":"2021-01-18T05:29:56.764Z","updated_at":"2024-07-02T16:37:32.794Z","phase":"","brief_title":"Risk Education and Assessment for Cancer Heredity","source_id_and_acronym":"NCT01346761 - REACH","lead_sponsor":"University of Utah","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 positive","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 positive"],"overall_status":"Completed","enrollment":" Enrollment 1012","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2016-04-14"}]